Significant health inequities pose challenges for those living with a rare disease

Harmonising European Newborn Screening

Current European landscape

The variation in screening programmes creates a concerning “postcode lottery” for newborns. A child born in one country may receive early diagnosis and life-changing treatment for a condition that would go undetected in a neighbouring nation until symptoms appear—often too late for optimal outcomes.

2011

EU Council Recommendation on Rare Diseases first highlights screening disparities

2018

European Reference Networks establish working groups on screening harmonization

2021

 ERDERA launched with €380 million funding under Horizon Europe

2023-2027

Implementation of coordinated screening expansion across member state

Key disparities

Number of conditions screened by country:

As shown in the chart, there are significant disparities in the number of conditions screened for newborns across European countries. Italy leads with 40 conditions, followed by Austria with 29. In stark contrast, the UK screens for only 9 conditions, and Romania for just 4, highlighting the “postcode lottery” that ERDERA aims to eliminate.

ERDERA strategic pillars

Data infrastructure

Creating shared European databases to evaluate screening outcomes, establish benchmarks, and validate new tests. This includes a federated data network linking biobanks, registries, and clinical databases while ensuring GDPR compliance.

Standardised protocols

Developing evidence-based guidelines for implementation that can be adapted to different healthcare systems, including cut-off values, confirmation protocols, and referral pathways for positive results.

Workforce development

Supporting training programs for laboratory personnel, clinicians, and genetic counsellors to ensure proper interpretation of advanced screening technologies and appropriate communication with families.

Collaborative governance

Facilitating dialogue between stakeholders—including patient representatives, healthcare providers, and policymakers—to guide evidence-based policy decisions and ethical implementation.

Economic impact

The economic case for coordinated expansion of newborn screening is compelling. For every €1 invested in comprehensive newborn screening, healthcare systems save an estimated €5-16 in treatment costs, social care, and productivity gains. Early detection and treatment of a single case of severe combined immunodeficiency (SCID) saves approximately €300,000 in emergency care costs that would otherwise be incurred before diagnosis. With ERDERA’s leadership, Europe has the opportunity to establish the world’s most advanced, equitable newborn screening ecosystem—ensuring that every child, regardless of birth location, benefits from early detection and intervention for life-threatening conditions.

Sources: ERDERA Strategic Plan 2022-2027; European Commission Health Programme Evaluation 2023; International Journal of Technology Assessment in Health Care (2021); Rare2030 Foresight Study.

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
Rare Disease Day 2026 visual representation

One year of ERDERA: the European alliance built to accelerate rare disease research reports first results

28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.

ERDERA's

search form